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HLA-G and HLA-E are immunoregulatory molecules that belong to HLA-Ib family. The role
of these molecules in the control of the immune response has been extensively analyzed,
both in physiological and pathological conditions. We have here summarized data present
in the literature regarding the interaction of these molecules in different settings. These
data suggested that HLA-G and -E co-operate in physiological conditions (i.e., establish-
ment of an immune tolerance at maternal/fetal interface during pregnancy), whereas their
role in the course of tumors or autoimmune/inflammatory diseases may be different or
even opposite. Future studies aimed at investigating the interaction between HLA-G and
HLA-E will help to clarify mechanism(s) underlying the regulation of immune effector cells
in health and disease.
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INTRODUCTION
HLA-G and HLA-E belong to non-classical HLA-class Ib family
that also includes HLA-F and HLA-H. In contrast with classical
HLA-Ia molecules (HLA-A, -B, and -C), these molecules display a
limited polymorphism, with a small number of proteins encoded
by few alleles (http://hla.alleles.org/nomenclature/stats.html, data
are summarized in Table S1 in Supplementary Material). More-
over, the function of HLA-class Ia and Ib molecules is different.
In fact, HLA-class Ia molecules bind peptides generated from
cytoplasmic proteins (in general represented by viral or tumor-
associated antigens) and interact with antigen-specific T-cell
receptor expressed on cytotoxic CD8+ T-cells, leading to the recog-
nition of virus infected or transformed cells (1). In addition, HLA-
class Ia molecules can interact with killer-inhibitory receptors
expressed on NK cells, thus modulating NK cell functions (2).
HLA-class Ib molecules are also able to bind peptides gener-
ated from intracellular antigens, but the main function of these
molecules is to modulate the immune response by interacting
with specific inhibitory receptors expressed on different immune
effector cells (3).
HLA-G is the best characterized among HLA-class Ib mole-
cules. Seven different isoforms are encoded by the same primary
mRNA through alternative splicing. Four isoforms (HLA-G1, -G2,
-G3, and -G4) retain the transmembrane domain and there-
fore are membrane-bound, whereas the other three isoforms
(HLA-G5, -G6, and -G7) retain the intron-4 and lose the trans-
membrane domain, and are therefore released as soluble mol-
ecules. In addition, soluble(s) HLA-G can be generated from
membrane-bound molecules, through the cleavage operated by
metalloproteases (4). In this respect, Rizzo et al. have recently
reported that metalloprotease 2, but not 9, is involved in this
process (5).
HLA-G expression is extremely restricted, being detected in
physiological conditions in placental trophoblast cells at maternal–
fetal interface during pregnancy (6), in thymus (7), cornea (8), nail
matrix (9), pancreas (10), monocytes (11), erythroid (12), and
endothelial precursors (13). However, HLA-G expression can be
also detected in different immune cell populations, such as T-cells
(14, 15), antigen-presenting cells (15–17), and in immunoreg-
ulatory cell populations, such as mesenchymal stem cells (18,
19). Nevertheless, HLA-G is up-regulated in different patholog-
ical conditions, such as transplantation, tumors, viral infections,
and inflammatory diseases (20, 21).
The role of this molecule is to regulate the immune response,
both in physiological and pathological conditions. This feature is
important at maternal–fetal interface, to avoid the lysis of semi-
allogeneic fetal tissue by maternal NK cells (22–25). Similarly, in
transplanted patients, an increased expression of surface HLA-G
(26) and an augmented concentration of serum sHLA-G (27) may
protect the transplanted organs from the rejection by the host’s
immune system. Conversely, HLA-G expression on transformed
cells (tumor cells and virus-infected cells) provides them with an
immune escape mechanism, avoiding the recognition and lysis
by cytotoxic immune effectors, such as NK cells and cytotoxic T
lymphocytes (28).
The immunoregulatory properties of this molecule are related
to the inhibition of the function of different immune cell pop-
ulations, such as T- and B-lymphocytes, NK cells, and antigen-
presenting cells. Such inhibition is mediated by the interaction of
HLA-G molecules with at least four inhibitory receptors expressed
on immune effector cells: immunoglobulin-like transcript (ILT)2
on NK cells, T- and B-lymphocytes; ILT4 on myeloid cells;
KIR2DL4 on NK cells and T-lymphocytes; and CD160 on NK
cells and T-lymphocytes (4).
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The expression of HLA-E mRNA can be virtually detected in
all nucleated cells. However, the surface expression of HLA-E, that
requires the presence of peptides derived from other HLA-class
I molecules and β2-microglobulin, is extremely restricted and it
has been related to cell activation (29). In fact, the function of
HLA-E is to bind peptides derived from the leader sequence of
HLA-class I molecules (HLA-A, -B, -C, and -G) and to present
them to NK cells through the interaction with the inhibitory recep-
tor CD94/NKG2A, thus inhibiting NK cell lysis against cells that
express normal levels of HLA-class I molecules. Conversely, cells
with low levels of HLA-class I expression generate low levels of
HLA-class I derived peptides and consequently display a low level
of HLA-E, thus allowing NK cell lysis (30). HLA-E can also interact
with CD94/NKG2C activating receptor on NK cells, in particular
when it binds peptides generated from HLA-G. This feature is
employed to activate NK cell lysis against HLA-G+ trophoblast
cells during placental invasion, leading to tissue remodeling (31).
However, it has been demonstrated that HLA-E affinity to the
inhibitory NKG2A/CD94 receptor is sixfold higher than its affin-
ity to the activating NKG2C/CD94 receptor (32). Finally, HLA-E
can present different peptides to HLA-E restricted effector cells.
Romagnani et al. have identified a CD8+ T-cell subset that recog-
nized different peptides associated to HLA-E on allogeneic cells,
thus highlighting their importance in transplantation and anti-
tumor immune responses (33). Moreover, it has been reported
that HLA-E present CMV-derived peptides to a subset of HLA-E
restricted CMV-specific CD8+ T-cells (34). This feature may be
relevant in the control of viral infections, since cytomegalovirus is
able to avoid the control of conventional CTL or NK cells. On the
other hand, Jiang et al. have demonstrated that peptides derived
from the signal peptide of Hsp60 and loaded on HLA-E are rec-
ognized by a subset of CD8+ regulatory T-cells that are able to
control self-reactive T-cells. The loss of this recognition may lead
to the development of autoimmune diseases (35).
In this review, we summarize for the first time data present in
literature regarding the interaction between HLA-G and HLA-
E, focusing on the role of this interaction in the control of
the immune response both in physiological and pathological
conditions.
HLA-G AND HLA-E CO-OPERATE IN PHYSIOLOGICAL
CONDITIONS
Several authors have demonstrated that HLA-G can influence and
modulate HLA-E expression. In particular, the expression of dif-
ferent isoforms of HLA-G may affect surface HLA-E expression,
which depends on the availability of peptides derived from HLA-
G molecules and other HLA-class I molecules. In this view, it has
been demonstrated that HLA-E surface expression was higher in
cells transfected with HLA-G1 or -G3 than in untransfected cells.
Moreover, HLA-E expression was higher in cells transfected with
HLA-G1 than in cells transfected with HLA-G3 (36). Similarly,
Ulbrecht et al. have demonstrated that the truncated isoforms
of HLA-G (HLA-G2, -G3, and -G4) are less efficient to provide
peptides to HLA-E molecules. Consequently, HLA-E expression
is lower in cells that express high levels of HLA-G truncated iso-
forms than in cells expressing HLA-G1 (37). This effect was likely
related to the ability of full-length transmembrane isoforms to
act as chaperone for HLA-E molecules, since the leader sequence,
that generates HLA-E binding peptides, is identical across differ-
ent HLA-G isoforms. However, data obtained by Sala et al. are
partially in contrast with this conclusion. They transfected JAR
cell line with HLA-G*0105N allele, which encodes a truncated iso-
form containing the leader peptide, the complete α1 domain, and
the first half of the α2 domain. Although this truncated HLA-
G1 protein is rapidly degraded, its leader sequence after cleavage
might still be available for binding to the HLA-E molecule. In fact,
transfected cells do not express HLA-G1 molecule on the surface,
but express a functional HLA-E molecule that is capable to inhibit
NK cell lysis by interacting with CD94/NKG2A receptor (38).
HLA-G and HLA-E are physiologically co-expressed on differ-
ent cell populations and can interact to modulate the immune
response. In this regard, Ishitani et al. have demonstrated that
HLA-E expression in trophoblast cells was strongly related to HLA-
G expression. In fact, surface expression of HLA-G was found in
extravillous trophoblasts, whereas sHLA-G production was found
in all placental trophoblasts, including villous cytotrophoblasts
and syncytiotrophoblasts. HLA-E expression was detected in all
cells that expressed either form of HLA-G, suggesting that HLA-
E requires peptides derived from all isoforms of HLA-G to be
expressed (39). Similarly, Shaikly et al. have demonstrated that
HLA-G and HLA-E co-localize on the surface of trophoectodermal
cells, and may regulate implantation through the regulation of the
effector functions of uterine leukocytes, by interacting with differ-
ent receptors expressed by different cell populations, leading to an
addictive effect (40). Moreover, it has been recently demonstrated
that mesenchymal stromal cells derived from gestational tissue
(in particular derived from the cord blood) are poorly immuno-
genic, and this feature is related to the co-expression of HLA-G
and HLA-E on their cell surface (41). Similarly, induced pluripo-
tent stem cells (iPSCs) express low levels of classical HLA-class I
molecules, but express high levels of HLA-G and HLA-E and are
able to avoid the recognition of HLA-restricted cytotoxic T-cells,
which become anergic when co-cultured with iPSCs (42).
HLA-G AND HLA-E INTERACTION MAY BE RELEVANT
DURING CANCER AND VIRAL INFECTIONS
HLA-G and HLA-E can co-operate to establish an immunosup-
pressive microenvironment in human tumors and viral infections,
facilitating the escape of transformed cells from the recognition
by the immune system.
In this view, de Kruijf et al. have demonstrated that in patients
with breast cancer either HLA-G or HLA-E expression correlated
with worse overall and event-free survival. This was observed only
in patients with tumors that display a loss of classical HLA-I mol-
ecules, thus suggesting that it may occur only when activated
NK cells are present. Notably, patients with tumors co-expressing
HLA-G and -E display the worst clinical outcome, thus suggesting
that the two molecules may co-operate shutting down NK cell-
mediated anti-tumor immune response (43). Similarly, it has been
demonstrated that HLA-G and -E co-expression correlated with
the presence of metastasis and with a worse event-free and overall
survival in patients with colon cancer, irrespective of the expres-
sion of HLA-class Ia molecules (44). Nevertheless, Malmberg et al.
have demonstrated that short-term ovarian carcinoma cell lines
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treated with IFN-γ become resistant to CTL-mediated lysis. Such
effect was mediated by increased HLA-G expression, which in turn
leads to up-regulation of HLA-E on tumor cells. Surface HLA-E
inhibits CTL activity by interacting with the inhibitory receptor
CD94/NKG2A (45).
In contrast with these studies, several groups have demon-
strated that HLA-G and -E may have different or even opposite
roles in tumor progression. In this respect, da Silva et al. have
demonstrated that HLA-G was overexpressed in the majority of
biopsies derived from patients with breast cancer, whereas HLA-E
expression was detected at low level in a small number of biopsies,
thus suggesting that, at least in this cohort of breast cancer patients,
HLA-G and -E interaction does not likely take place (46). Simi-
larly, HLA-G is specifically expressed in renal cell carcinoma and
not in normal renal parenchyma, whereas HLA-E is expressed in
both normal and pathological tissues. Moreover, a better relapse-
free survival was associated with a low HLA-G expression and
with a high HLA-E expression, thus suggesting a divergent role
of these molecules in the progression of this type of tumor (47).
On the contrary, Silva et al. have demonstrated that, in patients
with laryngeal lesions, HLA-G expression was detected in benign
and premalignant lesions and not in invasive carcinomas, whereas
HLA-E expression correlated with lesion grade, with a high expres-
sion in the draining lymph nodes of malignant lesions. Also, in this
case, however, an opposite role of HLA-G and -E in tumor progres-
sion was demonstrated (48). Similarly, in patients with cervical
carcinoma, HLA-G expression was detected in atypical glandu-
lar cells of undetermined significance and disappeared in cervical
intraepithelial neoplasia (CIN) and invasive cancer, whereas HLA-
E expression increased from CIN1 to CIN3 grade and the highest
HLA-E expression was detected in invasive cancer, thus suggesting
that HLA-E, rather than HLA-G, has a role in immune escape of
transformed cells (49). Finally, HLA-G and HLA-E expression was
detected in about 70% of biopsies from glioblastoma cells, and
co-expression was detected in 36% of cases. A high HLA-E expres-
sion was related to a better overall survival, whereas no correlation
was found between HLA-G expression and clinical outcome of
patients (50).
HLA-G and -E can also co-operate in the tumor microenvi-
ronment to induce local anergy (51). It has been demonstrated
that tumor-associated macrophages (TAM) express HLA-G on
their surface (52). HLA-G expressed and/or released by TAM
may interact with inhibitory receptors on NK cells stimulating
the release of pro-angiogenic cytokines, as reported (53). Kren
et al. have demonstrated that TAM may also express HLA-E (54),
which interacting with the inhibitory receptor CD94/NKG2A on
NK cells may further stimulate the release of immunosuppressive
cytokines from NK cells (55). Thus, HLA-E may collaborate with
HLA-G in the protection of TAM from NK cell lysis (30, 56) and
in the establishment of a tolerogenic tumor microenvironment.
HLA-G and HLA-E interaction may also take place during
viral infections. In this view, it has been demonstrated that rabies
virus is able to up-regulate both HLA-G and -E expression in
infected human neuronal precursors, and both molecules facili-
tate the immune escape of infected cells (57). Similarly, Vasireddi
and Hilliard have demonstrated that, in contrast with other her-
pesviruses, herpes B virus does not downregulate the expression
of HLA-Ia molecules. In contrast, HLA-G and -E expression is
significantly up-regulated in infected cells, thus again suggesting
a role of both molecules in the escape of infected cells from the
recognition of the immune system (58).
HLA-G AND HLA-E MAY HAVE OPPOSITE ROLES IN
INFLAMMATORY/AUTOIMMUNE DISEASES
Only few data are present in the literature regarding the role of both
HLA-G and -E in inflammatory/autoimmune diseases. However,
data obtained from our group in patients with juvenile idiopathic
arthritis (JIA) and multiple sclerosis suggest that HLA-G and -E
may have either an opposite or a synergistic role in the course of
these pathological conditions.
In fact, we have demonstrated that in JIA patients, HLA-G may
be more relevant as soluble molecule in the biological fluids, since
serum levels of sHLA-G are decreased in patients as compared to
controls. This may lead to an uncontrolled activation of immune
effector cells, which eventually migrate to the synovium, causing
tissue damage. In contrast, HLA-E appears to be more important
as surface molecule, since its expression is higher on infiltrating
synovial cells (mostly on B cells and monocytes) than in periph-
eral blood counterparts. This feature may be relevant to protect
autoreactive cells from NK cell-mediated lysis, thus exacerbating
local inflammation. Nevertheless, sHLA-E concentration in syn-
ovial fluid correlated with disease severity, thus suggesting that this
molecule may represent a marker of cell activation (59).
In contrast with these observations, data obtained in mul-
tiple sclerosis patients suggested that HLA-G and HLA-E can
co-operate in the resolution of inflammation. In fact, concentra-
tion of both sHLA-G and sHLA-E was higher in sera from patients
than controls (represented by patients with other neurological dis-
orders). More importantly, intrathecal synthesis of HLA-G and -E
was detected, and concentration of both molecules was increased
in cerebrospinal fluid (CSF) from MS patients as compared to
controls. Moreover, sHLA-E concentration was higher in clini-
cally stable patients than in those with clinically active disease.
Finally, CSF samples inhibited in vitro NK- and CTL-mediated
lysis. Such inhibition was higher using samples containing both
HLA-G and -E than samples containing HLA-G or HLA-E, or
devoid of both molecules. Taken together, these data suggested
that HLA-G and HLA-E co-operate in the inhibition of immune
effector cell function, and may have a role in the resolution of
neuroinflammation (60).
CONCLUDING REMARKS
We have here summarized for the first time the interaction between
HLA-G and -E in different settings (data are summarized in
Figure 1). We can conclude that, in physiological conditions, HLA-
E expression is strongly related to HLA-G, and normally both
molecules are involved in inducing anergy of activated immune
effector cells (mostly NK cells). Conversely, the interaction of
these molecules in pathological conditions may be variable, rang-
ing from a strong correlation and co-operation to an opposite
function and role in the progression of the disease (see Table 1).
Future studies aimed at a better knowledge of these interactions
may explain the mechanisms underlying the establishment of an
immunosuppressive microenvironment.
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FIGURE 1 | Interactions between HLA-G and HLA-E in the control of the
immune response. During pregnancy, HLA-G and -E are both expressed by
trophoblast cells and co-operate in the inhibition of NK cell functions, by
interacting with ILT2 and CD94/NKG2A receptors, respectively (A). In
different tumors, the loss of HLA-class Ia molecules activate NK cells through
KIR ligand mismatch. HLA-G and -E co-operate in the inhibition of activated
NK cells in the tumor microenvironment, facilitating the escape of tumor cells
from NK cell recognition (B). In renal cell carcinoma, HLA-G expression
correlates with worse prognosis, whereas HLA-E expression represents a
favorable prognostic marker. We can speculate that in this case HLA-G
preferentially interacts with inhibitory receptors on NK cells and CTL, whereas
HLA-E possibly interacts with CD94/NKG2C activating receptor on immune
effector cells (C). On the contrary, in laryngeal carcinoma, HLA-G predicts a
good prognosis, whereas HLA-E is associated with worse prognosis. In this
case, we speculate that HLA-G may predominantly interact with KIR2DL4
activating receptor, whereas HLA-E interacts with CD94/NKG2A inhibitory
receptor on NK cells and CTL (D). In multiple sclerosis patients, HLA-G and
HLA-E are expressed and released by resident cells in the central nervous
system (CNS), and both soluble molecules co-operate in the inhibition of NK
cells and CTL function, by interacting with inhibitory receptors (E).
Table 1 | Summary of HLA-G and HLA-E interactions in pathological conditions.
Disease Co-operation Correlation No correlation Opposite role
Tumors Breast cancer (43) x
Colon cancer (44) x
Ovarian carcinoma (45) x
Breast cancer (46) x
Renal cell carcinoma (47) x
Laryngeal carcinoma (48) x
Cervical carcinoma (49) x
Glioblastoma (50) x
Viral infections Rabies virus (57) x
Herpes B virus (58) x
Autoimmune disease Juvenile idiopathic arthritis (59) x
Multiple sclerosis (60) x
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